a method for treating patients to inhibit restenosis associated with coronary intervention , which comprises administering compounds of the class of aminobenzoic acids , specifically 2 -- aminobenzoic acid or its pharmaceutically acceptable salt at a dosage which is sufficient to maintain the plasma concentration at about 100μ molar for a period of time of less than three months .